GLP1 Protocol
Journey Guide

Month 9 on Semaglutide: Approaching Maintenance

Thirty-nine weeks of treatment. Three quarters of a year. Month 9 is where the steep portion of the weight-loss curve flattens for most users and the conversation begins to shift from active loss to long-term maintenance.

Composition representing a flattening curve and steady horizon

Most users are at 2.4mg by month 9, the maintenance dose under the Wegovy label. A meaningful minority sit at 1.7mg by choice — either because the lower dose is still producing loss, or because tolerability favored holding. Either is a legitimate place to be at this point.

The STEP 1 weight-loss curve at month 9 sits at roughly 13% cumulative loss from baseline, on average. The slope is noticeably gentler than at month 3 or month 6 — most of the rapid loss has happened, and the remaining months tend to add smaller, slower changes. This is the curve's natural shape, not a failure of the medication.

85%

Appetite Suppression

Deep, stable suppression at 2.4mg for most users. Hunger returns subtly in the day before the next injection but rarely interferes with adherence.

monitor_weight
Typical Cumulative Loss
11 - 16% of starting weight

Mean cumulative loss at month 9 in STEP 1 was approximately 13% from baseline. Higher responders are well above; slower responders sit below.

The Month 9 journey

The Month 9 Timeline

vaccines

Weeks 33-34

Steady at Maintenance Dose

2.4mg has been the routine for several months now. Injection days feel ordinary; side effects are background noise or absent.

monitoring

Weeks 35-36

Nine-Month Review

Many prescribers schedule labs again here — A1C, lipids, liver enzymes — and review the longer trend. The trajectory should be visibly flatter than at month 6.

check_circle

End of Month 9

Maintenance Planning

Conversations begin about what year two looks like. Continue at 2.4mg, hold at a lower dose, or eventually taper — all options depend on how close you are to your target and how confident the maintained behaviors feel.

What changes by Month 9

The body composition story is more visible now than at month 6. Three quarters of a year of reduced intake has reshaped how clothes fit, how stairs feel, how sleep goes. Many users report that resting heart rate, blood pressure, and lab markers (A1C, LDL, triglycerides) are noticeably better than baseline — sometimes more meaningful than the scale change.

Lean mass becomes a more pressing concern in this phase. Without protein and resistance training, more of the later loss tends to come from muscle. Prescribers commonly emphasize structured strength work twice a week and a protein floor around 1.4–1.6g per kilogram of body weight per day. The goal at month 9 is not just to keep losing — it is to keep losing the right tissue.

Mental shifts have settled. The novelty of the medication is long gone. What replaces it is a working pattern: smaller portions, fewer cravings, less time spent thinking about food. Some users describe a kind of quiet they did not realize was possible. Others find the absence of food noise mildly disorienting at first — both are normal.

Navigating Symptoms

check_circleQuiet GI
infoOccasional Constipation
infoMild Hair Shedding

Mild diffuse hair shedding can appear in months 6-12, usually linked to the rate of weight loss rather than the medication itself. It typically resolves once weight stabilizes. Adequate protein and iron are protective.

What other users say

What Users Report

starstarstarstarstar

Nine months, down 14%. The last two months have been slow but steady. My A1C is in the normal range for the first time in a decade.

— Eva R.

starstarstarstarstar_half

I'm a few pounds from goal. My doctor and I are starting to talk about what staying at 2.4mg looks like long-term versus stepping down. No rush.

— Daniel W.

Looking ahead

The last quarter of the year is mostly about consolidation. The curve is flatter, the habits are tested, and the maintenance plan starts to take shape. Continue to the Month 12 guide for the one-year review, or revisit the resources hub for plateaus, dose questions, and longer-term planning.